Mark J. Foley
2021
In 2021, Mark J. Foley earned a total compensation of $7.1M as CEO at Revance Therapeutics, a 19% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $425,700 |
|---|---|
| Option Awards | $1,141,226 |
| Salary | $660,000 |
| Stock Awards | $4,561,652 |
| Other | $317,338 |
| Total | $7,105,916 |
Foley received $4.6M in stock awards, accounting for 64% of the total pay in 2021.
Foley also received $425.7K in non-equity incentive plan, $1.1M in option awards, $660K in salary and $317.3K in other compensation.
Rankings
In 2021, Mark J. Foley's compensation ranked 1,711th out of 12,415 executives tracked by ExecPay. In other words, Foley earned more than 86.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,711 out of 12,415 | 86th |
Division Manufacturing | 631 out of 5,505 | 89th |
Major group Chemicals And Allied Products | 233 out of 2,375 | 90th |
Industry group Drugs | 196 out of 2,096 | 91st |
Industry Pharmaceutical Preparations | 133 out of 1,546 | 91st |
Pay ratio
| Mark J. Foley's Pay | $7,105,916 |
|---|---|
| Median Employee's Pay | $248,326 |
| Pay Ratio | 29to 1 |
In 2021, the annual total compensation of Mark J. Foley was $7,105,916.
The annual total compensation of the median employee at Revance Therapeutics was $248,326.
The ratio of Mark J. Foley's pay to the pay of median employee was therefore 29 to one.
Source: SEC filing on March 24, 2022.
Foley's colleagues
We found four more compensation records of executives who worked with Mark J. Foley at Revance Therapeutics in 2021.